Fungal infections following solid organ transplantation remain a major cause of morbidity and mortality. Candida species and Aspergillus fumigatus continue to account for the majority of these infections, although the attack rate is higher among recipients of organs other than kidneys because those patients receive more immunosuppressive therapy. Although amphotericin B re mains the drug of choice for treatment of invasive aspergillosis, its toxicity profile limits its widespread use. Recent experience suggests that fluconazole may be a safe and effective alterna tive for the treatment of fungal infections caused by Candida species or Cryptococcus neoformans. Prevention of fungal infections remains one of the most important goals in the field of transplantation. New approaches-such as the use of "preemptive therapy," or prophylaxis, for patients at greatest risk of developing infection-may assist in attainment of this goal.
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T he success o f organ transplantation has created an everincreasing patient population th at is at risk for invasive, and frequently life-threatening, fungal infection. Fungal infec tion occurs in zero to 14% o f renal transplant recipients [ 1 -6 ] and in as m any as 32% o f heart transplant recipients [7] [8] [9] [10] , 35% o f heart-lung and lung recipients [10] [11] [12] , 42% o f liver recipients [1 3- 1 6 ] , and 38% o f pancreas recipients [17] [18] , The differences in attack rates am ong recipients o f various transplanted organs are largely due to technical issues related to the transplant procedure and the tendency to adm inister more im m unosuppressive therapy to recipients o f organs other than kidneys (i.e., patients w ho have no alternative life support system, such as dialysis, if their allografts fail). The fungal infections that occur in these patients are due to five major pathogens: Candida species, Cryptococcus neoformans, the filam entous fungi (predom inantly Aspergillus species and organisms o f the M ucoraceae family), Pneumocystis carinii, and the agents causing geographically restricted systemic mycoses (i.e., histoplasm osis, coccidioidomycosis, and blas tomycosis).
T he incidence o f fungal infection following organ trans plantation, like that o f other forms o f opportunistic infection in this patien t population, is largely determ ined by the inter action betw een epidem iological (exposure) factors and the net state o f im m unosuppression [19] [20] [21] . These two ele ments interact in a sem iquantitative fashion: if the exposure is great enough, even patients w ho have a norm al im m une system may becom e ill; conversely, if the net state o f imm u-nosuppression is great enough, even m inim al exposure to potential pathogens will result in life-threatening infections [22] .
T he epidem iological, or exposure, factors o f im portance can be divided into two categories: those occurring w ithin the com m unity an d those occurring in the hospital setting. In the com m unity, the m ost im portant exposures are to en dem ic mycoses. Both recent and rem ote exposures are im portant, since three forms o f infection are recognized: (1) reactivated infection, in w hich infection acquired even m any years prior to the transplantation may reactivate from a dor m ant focus because o f the w aning o f previous im m unity (as a result o f the initiation o f im m unosuppressive therapy): (2) primary infection, in which an im m unosuppressed trans plant recipient develops progressive infection due to a fungal pathogen (first exposure); an d (3) reinfection, in w hich pre tran sp lan tatio n im m unity (acquired after previous exposure [s] ) has been atten u ated by im m unosuppressive therapy such th a t new exposure to the same fungal pathogen results in invasive infection. Regardless o f the type o f infection, the net result is invasive disease, frequently with systemic dissem ination.
Exposures w ithin the hospital are even m ore im portant than those occurring w ithin the com m unity. Invasive asper gillosis is the m ost significant nosocom ial fungal infection, predom inantly because o f the high case fatality rate am ong organ tran sp lan t recipients [23] . A lthough Aspergillus spe cies are ubiquitous in the environm ent and may cause dis ease in patients who live in or visit farming com m unities, construction an d renovation as well as co ntam inated air co n ditioning systems in the hospital en vironm ent have been as sociated with epidem ics o f invasive aspergillosis in im m uno suppressed patients, particularly organ transplant recipients [24] . Tw o patterns o f nosocom ial outbreaks are recognized: (1) dom iciliary, in which exposure occurs in the room or on the w ard where the patient is housed within the hospital (this type o f outbreak is relatively easily identified because o f the clustering o f cases in tim e and space), and (2) nondom iciliary, in which exposure occurs as the patient travels within the hospital for essential procedures (this type o f outbreak is probably m ore com m on than the dom iciliary type but is m ore difficult to recognize because there is no clustering o f cases in tim e an d space). R eported nondom iciliary outbreaks o f invasive aspergillosis in im m unosuppressed patients have stem m ed from exposure in a radiology suite, exposure in an operating room , an d even travel through a hospital area u n dergoing intensive construction [24] , A lthough high-efficiency particulate air filtering systems prevent domiciliary exposure, efforts for prevention o f nondom iciliary exposure are unsatisfactory in m any transplantation centers. Recently, em phasis has been placed on the developm ent o f protective masks and transportational devices for protecting transplant recipients from nondom iciliary exposure [25] , T he n et state o f im m unosuppression is a com plex function that is determ ined by the interaction o f a num ber o f factors: the doses o f an d duration o f therapy with different im m uno suppressive drugs and the sequence in which they are adm in istered; the presence or absence o f granulocytopenia, foreign bodies such as catheters, and devitalized tissue or undrained fluid collections (e.g., blood, urine, bile, or lym ph) as a co n sequence o f the transplantation operation; com prom ise o f the prim ary m ucocutaneous barrier to infection; the pres ence o f such m etabolic factors as protein-calorie m alnutri tion, urem ia, an d hyperglycem ia; and the presence o f infec tion with viruses, such as cytom egalovirus (CM V). T he im portance o f infection with these viruses in regard to the net state o f im m unosuppression is dem onstrated by the follow ing observation: over the past 10 years in the M assachusetts G eneral H ospital T ransplantation U nit, >90% o f the oppor tunistic infections due to Aspergillus species, P. carinii, and C. neoformans occurred in patients with active or recent in fection due to viruses such as CM V [22] , T he m ajority o f cases o f invasive aspergillosis have been due to unsuspected excessive exposure. ♦
Fungal Infection and the Tim etable of Infection After Transplantation
As im m unosuppressive regim ens have becom e standard ized, the tim e at w hich different infections occur after trans plantation has becom e predictable (figure 1). A ccording to this tim etable, the posttransplantation course can be divided into three phases: the first m onth, the period from the first m onth through the sixth m onth, ancFthe fate p e n o d 'fBeyond 6 m onths post-transplantation).
In the first m onth after transplantation, infectious disease syndrom es that occur are o f three types: those present in the tran sp lant recipient prior to transplantation; those conveyed with the allograft; an d the usual w ound, pulm onary, urinary. vascular-access-device, and drainage-catheter infections that occur in any patient undergoing com parable am ounts o f sur gery (although in im m unosuppressed transplantation pa tients the infections are associated with greater morbidity and m ortality). T h e following observations are specific to fungal infections.
(1) A lthough any active fungal infection present in an allograft recipient at the tim e o f transplantation could be exacerbated by im m unosuppression an d the operative proce dure, actively infected patients rarely receive transplants. A m ore frequent clinical challenge is the transplant recipient who is heavily colonized with a fungus at the tim e o f trans plantation. In such a setting, the com bination o f the trans plant operation an d initiation o f im m unosuppressive therapy perm its colonization to becom e invasive disease. For exam ple, there is an increased risk that invasive aspergillosis will occur during the first m onth after lung, heart, heart-lung, an d occasionally liver transplantation for recipients whose respiratory tracts were colonized with an Aspergillus species before the procedure. Likewise, there is an increased risk of deep candidal w ound infection in female recipients o f pan creas transplants whose vaginas are heavily colonized with a Candida species at the tim e o f transplantation [22] (2) Fungal infection can be transm itted with the allo graft. Rare cases o f histoplasm osis [26] an d cryptococcosis [27] in recipients o f renal allografts, secondary to unsus pected systemic infection in the donor, have been reported. M ore com m only, do n o r organs are contam inated with Can dida species secondary to unsuspected candidem ia in the do nors that is associated with preterm inal care (e.g., the useofa vascular access device, bladder catheters, and ventilatory support via an endotracheal tube). T he recipient may de velop infection (and mycotic aneurysm ) at the vascular su ture line [2 8 -3 1 ]. Careful assessm ent o f potential donors for both focal an d systemic fungal infection is as im portant as evaluation for oth er pathogens.
(3) M ore than 95% o f the infections during the first m onth after transplantation are the result o f technical prob lems associated with the surgical procedure and postopera tive m anagem ent [19, 20] , T he m ajority o f fungal i n f e c tio n s are due to Candida species. Patients with a functioning allograft > 6 m onths after transplantation can be divided into two groups on the basis of their risk for opportunistic fungal infection: those with satisfactory allograft function w hose conditions are being m aintained only with baseline im m unosuppressive therapy (these patients are at m inim al risk o f acquiring opportunistic fungal infection unless subjected to unusually intense envi ronm ental exposure) and those with a history o f significant acute an d chronic allograft rejection, w ho have received sig nificantly m ore im m unosuppressive therapy and frequently have chronic infection with the im m unom odulating viruses. Patients in this latter group (term ed the " chronic ne'er-dowells" ) are at increased risk for life-threatening opportunistic infection.
Fungal Infections of Particular Importance in the Organ Transplant Recipient Candidiasis
Candida species are by far the m ost com m on cause o f fun gal infection in the organ transplantation patient; the clinical syndrom es they cause range from the trivial (m ucocutaneous thrush) to the life-threatening (candidal sepsis with visceral seeding) [6, 20] , T he forms o f candidal infection that occur an d their incidence vary according to the type o f organ trans p lanted (figure 1). T he patterns m ay be sum m arized as fol lows.
(1) T he incidence o f candidal infections in the renal transplant recipient is betw een 3% an d 5% [1] [2] [3] [4] [5] [6] . Oral and esophageal candidiasis (particularly in diabetic patients and in those receiving broad-spectrum antibacterial therapy w ithout concom itant antifungal prophylaxis), vascular ac cess dev ice-related sepsis, an d candidal urinary tract infec tion are the m ost frequent forms o f infection. D eep w ound infection is uncom m on but may occur in diabetic patients, frequently as a mixed fungal an d bacterial process [18] , Iso lation o f a Candida species from the sputum is com m on; however, candidal pneum onia alm ost never occurs. T he im p o rtan t result o f colonization o f the respiratory tract by these organism s is concom itant colonization o f the skin, w hich in creases the risk o f vascular access-related candidem ia. Candiduria in the renal transplant recipient with diabetes or com prom ised bladder function is associated with an increase in obstructive uropathy caused by fungus balls, w hich may form at the ureteropelvic ju n ctio n [20] , In addition, candidal pyelonephritis o f the allograft may be associated with subse q u en t candidem ia.
(2) Fungi account for 20%-30% o f life-threatening infec tions in the liver transplant recipient; >85% o f these infec tions are candidal [13] [14] [15] [16] 
(3 ) T he incidence o f candidal infection in pancreas tran sp lant recipients approaches 10% [17, 18] . As indicated above, the predom inant infection is o f the deep w ound vari ety an d is associated with heavy vaginal colonization with Candida species.
(4) In lung and heart-lung transplantation, candidal co lonization may affect healing o f the bronchial anastam osis an d may increase the risk o f candidal m ediastinitis [10, 11] , U lcerative tracheobronchitis with form ation o f a pseudo m em brane following lung transplantation has been reported [32] .
(5 ) C andidal infection in the heart transplant recipient is sim ilar to that observed in renal transplant recipients: it is prim arily m ucocutaneous candidiasis and related to contam i nated venous access devices and drainage catheters [7] [8] [9] [10] , T hus, the m ajority o f candidal infections in transplant re cipients are the result o f technical m ishaps during the surgi cal procedure or are related to the postoperative m anage m ent o f vascular-access, bladder, or drainage catheters.
Aspergillosis
Invasive aspergillosis is the m ost im portant cause o f lifethreatening fungal infection in the organ transplant recipient [23] . In >90% o f cases the lungs are the portal o f entry, al though the sinuses and skin dam aged by other processes can also be the sites o f invasion [23, 33] . U lceration, necrosis, cartilage invasion, and form ation o f a pseudom em brane may occur in lung and heart-lung transplant recipients who have histologic evidence o f i n v a d e al^ergillasis [-3-2-]. O nce tissue infection develops, invasion o f blood vessels is the rule, ac co u nting for the three cardinal features o f invasive aspergil losis in the organ transplant recipient: tissue infarction, hem orrhage, and dissem ination with m etastatic seeding. T he presence o f dissem inated disease is closely related to m ortal ity. M ore than 50% o f transplant recipients w ithout dissemi nated disease m ay respond to therapy with am photericin (par ticularly w hen localized invasive aspergillosis is recognized early, im m unosuppression is reduced, and the allograft is functioning) [23] , O nce the infection has m etastasized, how ever, it is alm ost uniform ly fatal (even with the addition of rifampin to the therapeutic regim en) [23] , T he risk o f devel oping invasive aspergillosis is prim arily determ ined by epide miological (exposure) factors, b u t th e attack rate is higher in patients w ho have previously had CM V infection an d those requiring antirejection therapy (with additional steroids or with antilym phocyte antibody).
Cryptococcosis
For unclear reasons, cryptococcal infection rarely occurs during the first 4 -6 m onths after transplantation [19] , The portal o f entry for C. neoformans is the lung, from which it hem atogenously disseminates, particularly to the skin and the CNS an d less frequently to such sites as the urinary tract and skeletal system. M ost cryptococcal pulm onary disease is asym ptom atic or associated with flulike symptoms. These infections may be diagnosed only after a routine chest radio graph shows either an infiltrate or an asym ptom atic nodule. M etastatic infection o f the skin (resulting in papules, celluli tis, or nonspecific lesions) is the first sign o f disseminated cryptococcal infection in up to 30% o f patients [22] , Early biopsy o f unexplained skin lesions is encouraged, because treatm ent o f cryptococcal infection is m ore frequently suc cessful w hen it has n o t yet m etastasized to the CNS [34] , The presence o f cryptococcal antigen in the blood (or the isola tion o f the organism in blood cultures) may also indicate dissem inated infection.
C. neoformans is the classic cause o f subacute-chronic men ingitis in transplant recipients. Focal disease may also be pres ent, usually in association with meningitis. T he most com m on presenting sym ptom s are headache and fever; less com m on are an altered state o f consciousness an d meningeal signs (in contrast to the presenting sym ptom s and signs of hum an im m unodeficiency virus [H IV ]-infected patients). T he CSF-related findings o f lym phocytic pleocytosis, hypoglycorrhachia, an d an elevated protein concentration are com m on, although the presence o f cryptococcal antigen or o f the organism in culture confirm s the diagnosis. T he cryptococcal antigen test is quantitative an d useful n ot only for initial diagnosis but also as a m eans o f serial m e a s u r e m e n t of titers for determ ining the p atien t's response to therapy [35] .
Mucormycosis
M ucoraceae are uncom m on causes o f fungal infection in the organ transplantation patient and produce either a rap" idly progressive necrotizing pneum onia or rhinocerebral dis ease. T here are too few cases o f m ucorm ycosis to know w hich species are the m ost likely to cause invasive disease. A lthough classically associated with diabetic ketoacidosis, mucormycosis has been observed in transplant recipients who were euglycem ic but acidotic (e.g., because o f urem ia or a bicarbonate leak via the bladder following pancreatic trans plantation).
P. carinii Pneumonia
Now classified as a fungus, P. carinii is the m ost com m on I cause o f opportunistic pneum onia in transplant recipients; P. a carinii pneum onia occurs in ~1 0 % o f transplant recipients | during the first 6 m onths, if no prophylaxis is adm inistered j [36] [37] [38] [39] [40] 
Endemic, Geographically Restricted Systemic Mycoses
Histoplasm osis is the m ost frequently reported o f the three | major endem ic mycoses occurring in transplant recipients, if Patients living in regions o f endem icity (the Mississippi and 1 Ohio River valleys and m uch o f the M idwest and south-cen-3 tral U nited States) tend to develop primary disease, while : patients living in regions w here histoplasm osis is not en-I demic ten d to have reactivated disease. O utbreaks during which the attack rate am ong renal transplant recipients in ] regions o f endem icity rose from 0.5% to 2.1% have been re-I ported [41] . Risk factors for the developm ent o f invasive dis-1 ease, in addition to environm ental exposure, include anti-re-1 jection therapy. T he relationship betw een CMV disease and ; histoplasmosis is unclear. A lthough progressive dissemi-I nated disease develops in m ost transplant recipients, 66% I have the chronic form, presenting with nonspecific com plaints such as prolonged fever and skin lesions. CNS inj volvement is uncom m on and, surprisingly, the chest radio graph may be norm al for ~5 0 % o f patients. C ultures o f specimens from pulm onary and extrapulm onary sites are diagnostic, b ut results may not be available for 3 weeks. F un gal staining (o f bone m arrow aspirates, for exam ple) may provide a m ore rapid diagnosis. Serology is usually u nhelp ful. T he potential role o f the radioim m unoassay for serum and urine antigen in transplant recipients is under investiga tion.
Coccidioidom ycosis occurs less frequently than histoplas mosis an d has occurred mostly in renal and cardiac trans p lan t recipients [42] , Variable incidence rates occur in the regions in which it is endem ic (southw estern U nited States). Like histoplasm osis, reactivated disease tends to occur in re gions o f nonendem icity an d primary disease in regions o f endem icity. Again, dissem inated disease is the rule (the CNS and genitourinary, splenic, hepatic, an d jo in t sites are com m only involved). T he associated m ortality rate is >60%. Diagnosis depends on either culture or detection o f spherules in tissues. Bronchoscopy greatly im proves the diagnostic yield from pulm onary specim ens. T he high m ortality rate despite therapy (see below) an d the risk o f relapse after appar ently successful therapy have resulted in an ongoing contro versy: should transplantation continue in regions o f endem ic ity, an d should prophylaxis (e.g., with ketoconazole) be adm inistered to transplant recipients in w hom prior infec tion with Coccidioides im m itis is evident? Blastomycosis is rare, and experience with the disease in tran sp lan t recipients is therefore lim ited [43] , It m ost fre quently occurs as dissem inated disease, although patients usually present with m ore subacute pulm onary sym ptom s than are observed with histoplasm osis or coccidioidom yco sis. Diagnosis is by m eans o f culture or histopathology. Sero logical testing o f transplant recipients is unhelpful. T he m ost successful form o f antifungal prophylaxis in transplant recipients is the use o f trim ethoprim -sulfam ethoxazole to prevent P. carinii pneum onia [36, [56] [57] [58] , In addi tion, trim ethoprim -sulfam ethoxazole is quite effective in the prevention o f urosepsis, listeriosis, and nocardiosis [36] , In m any transplantation centers, trim ethoprim -sulfam ethoxa zole (80 mg trim ethoprim , 400 mg sulfam ethoxazole) is ad m inistered daily to all transplant recipients for the first 6 m onths after transplantation. It is our practice to reinstitute therapy with this agent for patients previously described as " chronic ne'er-do-w ells." T he efficacy o f nonabsorbable oral antifungal agents such as clotrim azole, nystatin, or am pho tericin in the prevention o f candidal infection derived from the gastrointestinal tract is less clear [59] , At ou r institution, nonabsorbable antifungal agents are used to prevent oral a n d /o r esophageal candidiasis in transplant recipients receiv ing antibacterial therapy and to decrease the colonization o f candidal species in the gut o f liver transplant candidates. T he potential role o f fluconazole as a prophylactic agent in liver transplantation is currently u nder investigation. * T here are currently three types o f preem ptive antifungal therapy in use at ou r center. Preem ptive therapy with itra conazole is used to prevent invasive aspergillosis (by decreas ing colonization) in transplant recipients whose respiratory tracts are colonized with an Aspergillus species ju st prior to transplantation or in the early posttransplantation period. Preem ptive therapy with fluconazole or itraconazole is used to reduce the risk o f dissem inated crjyjtococcal or Histoplasm a capsulatum infection, respectively, w hich may be triggered by surgical excision o f focal pulm onary nodules. Preem ptive therapy with fluconazole is used to prevent as cending infection and the form ation o f obstructing fungus balls in renal transplant recipients with asym ptom atic candiduria. Fluconazole is very effective in the treatm ent o f asym p tom atic pyuria associated w ith candiduria th at is due to Can. dida albicans an d Candida tropicalis b ut n ot with infection due to Torulopsis glabrata [34] 
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